Back to top

crispr: Archive

Zacks Equity Research

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

On Vertex Pharmaceuticals' (VRTX) Q1 earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and updates on the non-CF pipeline.

VRTXNegative Net Change NVAXPositive Net Change ACETPositive Net Change

Zacks Equity Research

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) Q1 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate CTX001.

VRTXNegative Net Change CRSPPositive Net Change APLTNegative Net Change

Bryan Hayes

Why April Has the Bulls Beaming

April is the best month for the Dow since 1950 - averaging about a 2% gain.

VRTXNegative Net Change

Zacks Equity Research

Intellia (NTLA) Depreciates 27% Over a Month: Here's Why

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

REGNNegative Net Change BDSIPositive Net Change NTLAPositive Net Change CRSPPositive Net Change